GlobeNewswire

Acapture, Sift Science to Bring Merchants World-Class Fraud Products

Dela

Enabling merchants to achieve higher conversion and authorization rates in real-time by reducing fraud, false positives and operational costs.

Amsterdam, The Netherlands - April 4, 2018 - Acapture, a global, omnichannel payment processor has partnered with Sift Science, a machine learning company that protects businesses from fraud and abuse. Using the smartest technology for fraud management in their joint effort to make online experiences smoother and safer, the two companies form a powerhouse for fighting ecommerce fraud and helping merchants maximize their revenue.

The partnership creates a single platform capable of managing every type of ecommerce fraud facilitated by Sift Science. Acapture's in-house global acquiring solutions offer access to payment data and insights into the payments journey of the end consumer. This data paired up with Sift Science's cutting-edge machine learning models make the ultimate fraud management solution to protect merchants in the fast-paced fraud landscape.

"We're delighted to have Sift Science as our trusted partner for our long-term mission to help merchants to fight fraud and deliver a better consumer experience" said Rudolf Booker, Acapture CEO. "It's a top challenge for them so it's a top priority for us! By working together, we are confident that the practical expertise in fraud management and machine learning of Sift Science combined with the complete insight into the entire transaction flow enabled by Acapture positions us as merchants' first choice for fraud management".

"Acapture's data and our machine learning models will drive business growth by reducing fraud, false positives, and operational costs," said Jason Tan, Sift Science CEO. "Combining our proven technology platforms, merchants automatically know who's trustworthy and risky. They no longer need to make a tradeoff between protecting and growing their business."

Ecommerce fraud has always been merchants' top of mind challenge that keeps on disrupting them from their core business, preventing them from making the most out of their incoming traffic. Due to the limitations on rule-based applications, many genuine transactions are rejected, resulting in legitimate customers being disappointed by their shopping experience. This rigid fraud prevention approach not only has a negative impact on conversion rates, but also on the brand's reputation especially nowadays, with social media platforms giving consumers a powerful voice.  Acapture's partnership with Sift Science aims to reduce the number of genuine customers being blocked and optimize conversions using customized, data enriched machine learning models. Merchants can ultimately focus on scaling-up their business and not be distracted by fraud.

###

About Acapture

Launched in 2015, Acapture is a new, modern, international payment service provider focused on maximizing the revenues of merchants around the globe. Acapture is affiliated to Payvision, one of the world's fastest-growing global card acquiring networks. Licensed as a payment institution by the Dutch Central Bank, Acapture combines with Payvision to help merchants grow their business globally. This is done through a complete data-driven omnichannel payment solution, capable of managing a payment at every stage, from checkout to fund collection to settlement.
Acapture's system features SlicePay for simplified allocation of funds to multiple parties from a single transaction, data science management for improved authorization rates, the best of human and machine intelligence platform for fraud detection and conversion optimization a one-day integration using one RESTful API, flexible, consolidated reporting, a streamlined reconciliation process, global card acquiring and the ability to handle 80+ of the most popular alternative payment methods and 150+ transaction currencies.
Together with Payvision, Acapture, was awarded Best PSP at the 2017 MPE Awards in Berlin. Find out more on www.acapture.com and follow Acapture on LinkedInTwitterFacebookYouTube and Corporate blog
For further information, please contact: Alina Geosanu | Corporate Communications Coordinator;
e-mail: alina@payvision.com

About Sift Science

Sift Science is a machine learning company that fuels business growth by protecting businesses and their customers from all vectors of fraud and abuse. Global brands such as Twitter, Airbnb, Yelp!, Shutterstock, Jet.com, Indeed and Wayfair rely on the Sift Science Digital Trust Platform for access to a global network of fraud data, 16,000+ fraud signals, and our unique ability to detect and prevent fraud in real time. Our platform was designed in accordance with industry best security practices, including SOC 2. To learn more, visit siftscience.com.

Find out more on https://siftscience.com/. For further information, please contact: Kristina Richmann, Pan Communications (for Sift Science): Kristina Richmann <krichmann@pancomm.com>




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Acapture BV via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Iconovo: kundprojekt blir framflyttat tre till sex månader8.11.2018 15:45Pressmeddelande

Fortsatt arbete med ett av Iconovos pågående kundprojekt kommer att flyttas fram tre till sex månader. Projektet avser utveckling av produkt anpassad för kund som ska svara för produktion och marknadslansering. Det aktuella arbetet var planerat att ske under fjärde kvartalet men beräknas ske under nästa år, och detta påverkar Iconovos omsättning under 2018 negativt med cirka 2 miljoner kronor. Orsaken är att kunden har beslutat att genomföra en mindre klinisk studie för att verifiera produkten innan nästa steg tas vilken omfattar investeringar i betydande mångmiljonbelopp i produktionskapacitet, baserat på Iconovos utveckling. Studien görs för kundens egna räkning och är inte villkorad av tillsynsmyndigheter. "Detta påverkar vårt resultat på kort sikt, men det faktum att kunden har beslutat att göra en betydande investering i faktisk produktion betyder att vi med stor säkerhet kan se fram emot licensintäkter under en lång tidsrymd framöver i samband med att produkten lanseras på markna

Stillfront Group AB: Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 20187.11.2018 14:34Pressmeddelande

PRESSMEDDELANDE 7 november 2018 Inbjudan till Stillfront Groups kvartalsrapport för tredje kvartalet 2018 Stillfront Groups kvartalsrapport för det tredje kvartalet 2018 kommer att publiceras klockan 07.00 den 22 november 2018. En webbsänd telefonkonferens kommer att hållas klockan 10.00 samma dag där Jörgen Larsson, VD och Sten Wranne, CFO, kommenterar resultatet. Presentationen och rapporten kommer efter presentationen att finnas tillgänglig på www.stillfront.com Webbsändningen nås på adressen: https://tv.streamfabriken.com/stillfront-q3-2018 För att delta via telefon, vänligen ring: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FÖR YTTERLIGARE INFORMATION, VÄNLIGEN KONTAKTA: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com OM STILLFRONT Stillfront är en oberoende utvecklare, förläggare och distributör av digitala spel - med visionen att bli en ledande indie-spelutvecklare och förläggare. Stillfront är verksamt genom tio näst intill självständiga dotte

Stillfront Group AB: Invitation to Stillfront Group Q3 presentation7.11.2018 14:34Pressmeddelande

Invitation to Stillfront Group Q3 presentation Stillfront Group interim report for the third quarter 2018 will be published at 07.00 CET on 22 November 2018. A presentation of the report will be held the same day at 10.00 CET via telephone conference or audiocast where Jörgen Larsson, CEO and CFO Sten Wranne are to comment on the report. The presentation can be viewed live at https://tv.streamfabriken.com/stillfront-q3-2018 To participate via phone please call: SE: +46 8 566 426 63 UK: +44 20 300 898 01 US: +1 8 557 532 235 FOR FURTHER INFORMATION, PLEASE CONTACT: Sofia Wretman, IR Phone: +46 708 11 64 30 sofia@stillfront.com ABOUT STILLFRONT Stillfront is a group of independent creators, publishers and distributors of digital games - with a vision to become the leading group of indie game creators and publishers. Stillfront operates through ten near-autonomous subsidiaries: Bytro Labs in Germany, Coldwood Interactive in Sweden, Power Challenge in the UK and Sweden, Dorado Online Games

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Modus Therapeutics announces FDA Acceptance of Sevuparin IND for the treatment of sickle cell disease7.11.2018 08:30Pressmeddelande

STOCKHOLM, November 7, 2018. Karolinska Development's portfolio company Modus Therapeutics announces today that the U.S Food & Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application to initiate a Phase I clinical trial with subcutaneous sevuparin for the treatment of sickle cell disease (SCD) FDA has decided to accept Modus Therapeutics' IND application of sevuparin for the treatment of SCD. Sevuparin is an innovative, proprietary modified polysaccharide drug with anti-adhesive, anti-aggregate and anti-inflammatory effects due to its multimodal mechanism of action. It has the potential to restore blood flow and prevent further microvascular obstructions in children and adults with SCD. At present, sevuparin is being evaluated as an intravenous infusion in a Phase II study in SCD patients with ongoing painful crises (also called vaso occlusive crises, VOC). In order to broaden the clinical scope and utility of sevuparin in the treatment of SCD, t

Oboya participates in China International Import Expo1.11.2018 15:00Pressmeddelande

Newsletter Lerum, 1th November 2018 Oboya Horticulture Industries AB (publ) ("Oboya"), a global manufacturer and supplier of products and services for the cultivation industry, will participate in China International Import Expo in Shanghai, China. China International Import Expo (CIIE) is a six-day fair held from November 5 to November 10, 2018 at the National Convention & Exhibition Center in Shanghai, China. This fair brings together companies, exhibitors and professional buyers from all over the world. The fair creates new channels for companies from different countries and regions and provides the opportunity to do business, strengthen cooperation and promote trade. Oboya's strategy is to work globally in the various markets in the cultivation and flower industry, which it's important for Oboya to participate in the major trade shows. Oboya has its own booth at the fair and will show/marketing the European cultivation products and technology to the Chinese market. The purpose of t

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum